GATA3 mRNA expression, but not mutation, associates with longer progression-free survival in ER-positive breast cancer patients treated with first-line tamoxifen for recurrent disease

Highlights • GATA3 mutations were identified among 14% of ER-positive breast cancer patients • GATA3 mutations did not predict the response to tamoxifen for advanced disease • GATA3 mutations associate with an increased expression of GATA3 mRNA • GATA3 mRNA level is an independent predictor of longe...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer letters 2016-06, Vol.376 (1), p.104-109
Hauptverfasser:	Liu, Jingjing, Prager – van der Smissen, Wendy J.C, Look, Maxime P, Sieuwerts, Anieta M, Smid, Marcel, Meijer – van Gelder, Marion E, Foekens, John A, Hollestelle, Antoinette, Martens, John W.M
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents, Hormonal - adverse effects Antineoplastic Agents, Hormonal - therapeutic use Biomarkers, Tumor - genetics Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - genetics Breast Neoplasms - metabolism Breast Neoplasms - mortality Cancer therapies Chemotherapy Chi-Square Distribution Disease-Free Survival DNA Mutational Analysis Expression Female GATA3 GATA3 Transcription Factor - genetics Gene expression Gene Expression Regulation, Neoplastic Hematology, Oncology and Palliative Medicine Humans Kaplan-Meier Estimate Logistic Models Medical prognosis Multivariate Analysis Mutation Neoplasm Recurrence, Local Odds Ratio Proportional Hazards Models Protein expression Proteins Receptors, Estrogen - antagonists & inhibitors Receptors, Estrogen - metabolism Recurrent breast cancer Retrospective Studies Risk Factors RNA, Messenger - genetics Rodents Selective Estrogen Receptor Modulators - adverse effects Selective Estrogen Receptor Modulators - therapeutic use Tamoxifen Tamoxifen - adverse effects Tamoxifen - therapeutic use Time Factors Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • GATA3 mutations were identified among 14% of ER-positive breast cancer patients • GATA3 mutations did not predict the response to tamoxifen for advanced disease • GATA3 mutations associate with an increased expression of GATA3 mRNA • GATA3 mRNA level is an independent predictor of longer PFS during tamoxifen therapy • Other mechanisms, besides GATA3 mutations, exist that underlie high GATA3 levels
ISSN:	0304-3835 1872-7980
DOI:	10.1016/j.canlet.2016.03.038